Kuslima “Tina” Shogen founded Alfacell Corporation in 1981 to pursue research she initiated as a Development Biology student in the University Honors Program at Fairleigh Dickinson University (FDU). She has served as Chief Executive Officer of Alfacell since 1986, and Chairman of the Board of Directors since 1996. Prior to Alfacell, she was a Teaching Fellow and faculty member at FDU, the founder and president of a biomedical research consortium specializing in Good Laboratory Practices and animal toxicology, and a consultant for Lever Brothers. Dr. Shogen has received numerous awards for achievements in academia, science and industry, including the first-ever Pioneer Award from the Mesothelioma Applied Research Foundation and the FDU Pinnacle Award. She was also named to the inaugural PharmaVOICE 100 List of Most Inspiring People in the healthcare industry, and was one of only 27 CEO’s recognized. Dr. Shogen has authored numerous scientific papers and articles, been an invited presenter and panelist at several conferences, and served as the keynote speaker at The International Meeting on Ribonucleases on multiple occasions. Dr. Shogen earned a B.S., M.S. and D.Sc. from FDU. She is a Phi Beta Kappa graduate.

Lawrence Kenyon is a Certified Public Accountant with 18 years of experience as a senior executive in the biotechnology and financial services industries. Prior to joining Alfacell, from September 2000 thru August 2006, Mr. Kenyon served as Executive Vice President, Chief Financial Officer and Corporate Secretary with NeoPharm Inc., a publicly traded biopharmaceutical company. From October 1999 until September 2000, he was Senior Vice President of the Gabelli Mathers Fund, a regulated investment company, and from March 1988 until October 1999 Mr. Kenyon held a variety of positions with Mathers and Company Inc. an investment management firm, most recently serving as chief financial officer for both Mathers and Company Inc. and Mathers Fund Inc. Kenyon began his career with Arthur Andersen & Co. after receiving a bachelor's degree in accounting from the University of Wisconsin -- Whitewater.

Andrew Aromando has over 13 years of experience in the pharmaceutical industry, holding positions of increasing responsibility in business development, strategic planning, management consulting, market research, marketing and sales. Prior to joining Alfacell, he was a senior executive at Innovex, a division of Quintiles Transnational Corporation, from 2000 to 2004. From 2002 to 2004, Mr. Aromando served as Vice President, Business Development, North America, where he led the development and execution of commercial strategies and tactics for branded pharmaceutical products across many therapeutic areas, including oncology. He also successfully managed significant strategic partnerships with several major, mid-size and emerging pharmaceutical, biotechnology and medical device companies. Prior to Innovex, Mr. Aromando held senior management positions at Strategic Business Research (1998 to 2000) and LARK Marketing Support Services (1994 to 1998), two leading pharmaceutical industry service suppliers. He began his career in the industry in 1992 as a sales representative with Sandoz Pharmaceuticals. Mr. Aromando holds a B.A. from The College of New Jersey and a M.A. from Rutgers University.

Diane Scudiery has over 25 years of domestic and international experience in the pharmaceutical industry. She has held positions of increasing responsibility in clinical operations, data management and regulatory affairs at leading pharmaceutical and biotechnology companies. She has extensive experience in managing clinical programs for oncology products, and in the development and execution of facilitating regulatory activities with the FDA, EMEA, Health Canada and the TGA (Australia). She has also led successful efforts to obtain Orphan Drug designations in the US and Europe, as well NDA orphan drug approvals. Prior to joining Alfacell, Ms. Scudiery served as Director of Clinical Research at Enzon Pharmaceuticals, and was a key member of the team responsible for regulatory approvals of their first two marketed products, ADAGEN® and ONCASPAR.® Prior to Enzon, Ms. Scudiery held clinical and regulatory positions at Aventis and Schering-Plough. Ms. Scudiery earned a B.A. from William Paterson University, a M.Ed. from Rutgers University and a M.A. from Farleigh Dickinson University.

David Sidransky. M.D., joined the Board of Directors in May 2004 and serves as the Chairman of the Company's Scientific Advisory Board. Dr. Sidransky is a founder of several private biotechnology companies and has served on numerous scientific advisory boards of many private and public companies, including Medimmune, Telik, Roche and Amgen. He was formerly on the board of scientific counselors at the NIDCR and he is currently a member of the Recombinant DNA advisory committee at the National Institute of Health NIH (RAC) and the Board of Directors of ImClone Systems. Dr. Sidransky is on numerous editorial boards and is senior editor of Clinical Cancer Research. Currently, Dr. Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. In addition, he is Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has over 250 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda and Richard Rosenthal Award from the American Association of Cancer Research.

John Brancaccio was appointed to the Alfacell Board of Directors in January 2004. Mr. Brancaccio has been the chief financial officer of Accelerated Technologies, Inc., an incubator for venture backed medical device companies. He also serves on the boards of Callisto Pharmaceuticals, Inc. and FermaVir Pharmaceuticals, Inc. both of which are publicly traded biopharmaceutical companies where he is chairman of their respective Audit Committees. He was the secretary and treasurer of Memory Pharmaceuticals Corporation from December 2003 to March 2004 after serving in the capacity of their acting chief financial officer from May 2002 to December 2003. Prior to Memory Pharmaceuticals, Mr. Brancaccio held the positions of chief financial officer and chief operating officer of Eline Group, a publicly traded entertainment and media company, where he oversaw the roll up of several related companies into the group and completed private equity financing placements. Prior to joining Eline Group, he held a number of senior executive positions in public and private companies including Atlantic Pharmaceuticals, Zalnbon Corporation, Deven International and Health Learning Systems. During his tenure with these companies lieparticipated in initial public offerings and the negotiating of licensing and development agreements within both the pharmaceutical and biotechnology industries. He is a retired Certified Public Accountant and a graduate of Seton Hall University.

Stephen Carter. M.D., joined the Alfacell Board of Directors in May 1997. Dr. Carter has over 30 years of experience in oncology research and development in academia and industry. Dr. Carter most recently served as Senior Vice President, Clinical and Regulatory Affairs for SUGEN, Inc., a San Francisco-based biotechnology and pharmaceutical company, now a subsidiary of Pfizer. Prior to SUGEN, he was Senior Vice President, Research & Development, for Boehringer Ingelheim Pharmaceuticals, Inc. from 1995 to 1997. From 1982 to 1995, Dr. Carter served in several executive roles in R&D at Bristol-Myers Squibb Company, including five years as Senior Vice President, Worldwide Clinical Research & Development, Pharmaceutical Research Institute, and played a leading role in gaining regulatory approval for widely-used anticancer and AIDS therapies. From 1976 to 1982, he established and directed the Northern California Cancer Program. Prior to this, he held a number of positions at the National Cancer Institute from 1967 to 1976, including the position of Deputy Director at the National Institutes of Health. He has also been a faculty member of the medical schools of Stanford University, the University of California at San Francisco, and New York University. Dr. Carter has published extensively on the development of anticancer drugs, was the co-founding editor of journals devoted to cancer therapeutics or immunology, and has served on the editorial boards of a number of additional journals dedicated to cancer treatment. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the Society for Surgical Oncology. Dr. Carter earned his B.A. from Columbia University and his M.D. from New York Medical College.

Donald Conklin joined the Alfacell Board of Directors in May 1997. Prior to his involvement with the Company, Mr. Conklin was a senior executive with Schering-Plough, a major worldwide Pharmaceutical firm. During his more than 35 years with Schering-Plough, he held a variety of key management positions within the firm. From 1986 to 1994, he served as President of Schering-Plough Pharmaceuticals. In this position, he was responsible for worldwide pharmaceutical operations, including the launch of INTRON A® (interferon alfa-2b). Prior to this, Mr. Conklin had served as President of Schering USA and had held a variety of executive marketing positions in the United States, Europe, and Latin America. Immediately preceding his recent retirement, he was Chairman of Schering-Plough Health Care Products and an Executive Vice President of Schering-Plough Corporation. Mr. Conklin received his B.A. with highest honors from Williams College and his MBA degree from the Rutgers University School of Business. He currently serves on the Board of Directors of Vertex Pharmaceuticals, CytoTherapeutics, Biotranplant, and Ventiv Health.

James Loughlin joined the Alfacell Board of Directors in January 2004. Elected to partnership in 1973, Mr. Loughlin remained with KPMG LLP ("KPMG") until September 2003, when he retired from the Pharmaceuticals Practice, Life Sciences and Chemicals division. During his career, Mr. Loughlin served in various executive positions throughout KPMG, including Managing Partner of the firm's Milwaukee, Wisconsin office, Partner-in-Charge of Human Resources for the United States in the firm's National Executive Office in New York, and Partner-in-Charge of the Audit Practice in the firm's Short Hills, New Jersey office. Mr. Loughlin was also elected to and served on the firm's Board of Directors from 1994 until 1998. He gained extensive experience serving multinational pharmaceutical manufacturing and distribution companies. Mr. Loughlin is a Certified Public Accountant, and received his B.S. in Accounting from St. Peter's College.

Paul Weiss, Ph.D., joined the Board in February 2003. Dr. Weiss is currently a Managing Director at Venture Investors, LLC, a Madison, Wisconsin-based, early stage, life science focused, venture capital group. Prior to this, Dr. Weiss was President of the Gala Biotech business unit of Cardinal Health (now Catalent Pharma Solutions) from February 2002 until October 2007. He had served as a director on Gala's Board from 1998 to 2001, when he joined the management team as Senior Vice President of Business Development. He later became President of Gala and remained so during the acquisition of Gala by Cardinal Health in 2003, and then the acquisition of Gala (and other Cardinal Health businesses) by The Blackstone Group in 2007. Prior to joining Gala, Dr. Weiss was Vice President of Technology and Product Licensing at 3-Dimensional Pharmaceuticals (3DP) from 1998 to 2001, which went public in 2001 and was later acquired by Johnson & Johnson. Prior to joining 3DP, Dr. Weiss was Director of Licensing for Wyeth Pharmaceuticals. Dr. Weiss holds a Ph.D. in Biochemistry and an MBA from the University of Wisconsin-Madison and a B.Sc. in Biochemistry from Carleton University Institute of Biochemistry in Ottawa, Ontario.